Implementing toxicity testing best practices in every phase of drug research
In researching and developing new drug therapies, toxicity is critical from the earliest phases of development.
Two factors largely drive the discontinuation of a drug development program, contributing to the low success rate for clinical trials: poor efficacy in humans and adverse events. Findings related to these factors as well as the inherent properties of the drug itself can be used to improve the overall success rates of a drug development program.
In this report, we look at how each step in the drug discovery phase is crucial to improving success rates and explore best practices that could be incorporated into the workflow.